Attention
Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.
Overcome Preclinical to Clinical Translatability, Patient Selection & Resistance Hurdles with Novel Combination Cancer Immunotherapies Towards Safe & Effective Treatments for Patients
Welcome to the Novel Combination Cancer Immunotherapy Summit
Supercharging Immunotherapies with Rational Combinations of ICIS, OVs, Adoptive Cells & Beyond
The field of oncology is moving away from targeted monotherapies due to exhibited tumor resistance, low efficiency and off-target effects. Therefore, combination cancer immunotherapies are taking center stage as the next frontier in oncology but challenges remain before they can become the mainstream therapeutic strategy over the current standards of care.
For the first time ever, immuno-oncology pioneers will unite at the Novel Combination Cancer Immunotherapy Summit 2024, to revolutionize cancer treatments through the rational selection and development of effective and durable combination therapies with checkpoint inhibitors, ADCs, adoptive cell therapies, oncolytic viruses and beyond.
From overcoming resistance and relapse to improving patient selection, protocol design, regulatory adherence and route to market, join forces with leading experts in the field such as Merck, Pfizer and Amgen to advance your combination strategies. Stay ahead of the curve with scientific advancements that will unleash the true power of combination cancer immunotherapies by fast-tracking your pipelines towards commercially successful and therapeutically valuable assets.
Key Sessions
Navigating the Maze: Challenges & Strategies for Combination Immunotherapies in Early-Phase Clinical Trials
Yuanming Xu, Associate Director, Pfizer
Targeting the Immunosuppressive Tumor Microenvironment through Combining the TVAX Vaccination & Adoptive Cell Therapy Platform with OV
Wayne Carter, Chief Executive Officer, TVAX Biomedical
Rational Combinations to Enhance efficacy of Bispecific T cell Engagers (BiTEs) in Solid Tumors
Raj Ganesan, Executive Director, Amgen
Using Complementary Pre-Clinical Models to Increase Success in Biomarker Discovery for ADC ICI combinations
Geoff Stone, Director, Biotherapeutics, Exelixis
Anchored Immunotherapy as a Strategy for Targeting Cytokine Retention in the Tumor Microenvironment to Promote Tumor Regression Without Systemic Toxicity
Howard Kaufman, Chief Executive Officer, Ankyra Therapeutics